A Study of Regorafenib in Advanced Pancreatic Cancer Patients

Summary

This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.

Timeline

Start

2014-06-06

Primary completion

2017-06-28

Completion

2017-06-28

Drugs

Indications